Department of Paediatric Pneumology and Immunology, Charité University Medical Centre, Berlin, Germany.
J Allergy Clin Immunol. 2012 Oct;130(4):894-901.e5. doi: 10.1016/j.jaci.2012.05.053. Epub 2012 Jul 25.
IgE sensitization against grass pollen is a cause of seasonal allergic rhinitis.
We sought to investigate the evolution at the molecular level and the preclinical predictive value of IgE responses against grass pollen.
The German Multicentre Allergy Study examined a birth cohort born in 1990. A questionnaire was administered yearly, and blood samples were collected at 1, 2, 3, 5, 6, 7, 10, and 13 years of age. Grass pollen-related seasonal allergic rhinitis (SARg) was diagnosed according to nasal symptoms in June/July. Serum IgE antibodies to Phleum pratense extract and 8 P pratense molecules were tested with immune-enzymatic singleplex and multiplex assays, respectively.
One hundred seventy-seven of the 820 examined children had SARg. A weak monomolecular/oligomolecular IgE response to P pratense was observed very frequently before SARg onset. These initial IgE responses increased in concentration and molecular complexity during the preclinical and clinical process. A typical progression of IgE sensitization was observed: Phl p 1 (initiator in >75% of cases); then Phl p 4 and Phl p 5; then Phl p 2, Phl p 6, and Phl p 11; and then Phl p 12 and Phl p 7. At age 3 years, IgE sensitization predicted SARg by age 12 years (positive predictive value, 68% [95% CI, 50% to 82%]; negative predictive value, 84% [95% CI, 80% to 87%]). At this preclinical prediction time, the number of recognized molecules and the serum levels of IgE to P pratense were significantly lower than at 3 or more years after SARg onset.
The IgE response against grass pollen molecules can start years before disease onset as a weak monosensitization or oligosensitization phenomenon. It can increase in serum concentration and complexity through a "molecular spreading" process during preclinical and early clinical disease stages. Testing IgE sensitization at a preclinical stage facilitates prediction of seasonal allergic rhinitis at its molecular monosensitization or oligosensitization stage.
IgE 对草花粉过敏是季节性过敏性鼻炎的一个原因。
我们旨在研究 IgE 对草花粉反应的分子水平演变和临床前预测价值。
德国多中心过敏研究对 1990 年出生的队列进行了研究。每年进行一次问卷调查,并在 1、2、3、5、6、7、10 和 13 岁时采集血样。根据 6/7 月的鼻部症状诊断与草花粉相关的季节性过敏性鼻炎(SARg)。使用免疫酶单plex 和 multiplex 检测法分别检测 Phleum pratense 提取物和 8 个 P pratense 分子的血清 IgE 抗体。
在 820 名接受检查的儿童中,有 177 名患有 SARg。在 SARg 发病前,经常观察到对 P pratense 的微弱单分子/寡分子 IgE 反应。这些初始 IgE 反应在临床前和临床过程中增加了浓度和分子复杂性。观察到典型的 IgE 致敏进展:Phl p 1(在>75%的病例中是起始物);然后是 Phl p 4 和 Phl p 5;然后是 Phl p 2、Phl p 6 和 Phl p 11;然后是 Phl p 12 和 Phl p 7。在 3 岁时,IgE 致敏可预测 12 岁时的 SARg(阳性预测值,68%[95%CI,50%至 82%];阴性预测值,84%[95%CI,80%至 87%])。在这个临床前预测时间,识别分子的数量和 P pratense 的 IgE 血清水平明显低于 SARg 发病后 3 年或更长时间。
对草花粉分子的 IgE 反应可以在疾病发病前数年开始,表现为微弱的单致敏或寡致敏现象。它可以通过临床前和早期临床疾病阶段的“分子扩散”过程增加血清浓度和复杂性。在临床前阶段进行 IgE 致敏测试有助于在分子单致敏或寡致敏阶段预测季节性过敏性鼻炎。